Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Anifrolumab, Mycophenolate mofetil, Sm-Tregs, CAR T-Cell, CV Risk factors,

October 2021

N Engl J Med 2020:211–20

Morand et al demonstrate a greater BICLA response at Week 52 for patients treated with anifrolumab versus those treated with placebo.